Encell Signs 2 Billion KRW CDMO Contract with Korean Biopharmaceutical Company

CDMO Contract for Clinical Trial Drugs Worth 2 Billion KRW Signed with Domestic Biopharmaceutical Developer
Encell to Provide One-Stop Services with Global-Level GMP Facility
CEO Jang Jongwook: "Aiming for Global Market Expansion through Partnerships"

On May 28, Encell, a company specializing in advanced biopharmaceutical CDMO and new drug development, announced that it has signed a CDMO (Contract Development and Manufacturing Organization) contract for clinical trial drugs worth approximately 2 billion KRW with a domestic advanced biopharmaceutical development company.

This contract is valued at 1,917,490,000 KRW for the client company's clinical trial drug CDMO services, and the contract period runs until July 31 of next year. Key details of the contract are not disclosed in accordance with a confidentiality agreement between the two companies.

Encell ranks first in sales and market share in the domestic CGT (cell and gene therapy) CDMO sector. Encell is the only company in Korea with a global-level GMP (Good Manufacturing Practice) facility capable of simultaneously producing both cells and viruses. Through this, it provides one-stop services and delivers optimal CDMO solutions to clients via a differentiated production and quality management system.

Jang Jongwook, CEO of Encell, stated, "Encell is providing the best possible services to clients through optimized processes and quality management in response to continuously increasing domestic and international CDMO demand," and added, "We will do our utmost to establish partnerships with overseas companies and target the global market."

Meanwhile, Encell is expanding its collaborations with domestic and international advanced drug development companies, having signed a CMO contract with a major global pharmaceutical company in December of last year following Novartis and Janssen. The company is making company-wide efforts to secure Adeno-Associated Virus (AAV) CDMO orders, which it has identified as a next-generation growth engine.